• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

TytoCare Receives FDA Clearance for AI-Powered Tyto Insights for Wheeze Detection

by Syed Hamza Sohail 03/15/2023 Leave a Comment

TytoCare and Overlake Partner to Expand Virtual Care Offerings

– TytoCare, a virtual care company enabling accessible, high-quality primary care from home, today announced that it received FDA clearance for its Tyto Insights for Wheeze Detection, paving the way for its rollout in the US.

– The wheeze detection algorithm expands the company’s existing AI-powered Tyto Insights™ smart diagnostic capabilities, filling the quality gaps currently experienced with traditional telehealth and alleviating challenges imposed by the ongoing shortage of healthcare professionals.

AI-Driven Upgrades to TytoCare’s Home Smart Clinic Solutions to Expand Acute Care and Chronic Condition Management

Tyto InsightsTM for Wheeze Detection is designed to aid in the clinical assessment of lung sound data for adults and children aged two and above, enabling clinicians to accurately diagnose respiratory conditions remotely. Fueled by TytoCare’s own database of lung sounds – the largest of its kind – the AI-powered decision support software automatically analyzes lung sounds recorded by TytoCare’s FDA-cleared handheld remote exam device’s stethoscope to determine whether wheezing is detected. Whenever a remote lung exam is carried out with TytoCare, Tyto Insights for Wheeze Detection prompts a clinician if a specific abnormal lung sound suggestive of wheezing is suspected. 

The FDA clearance comes as TytoCare is continually strengthening its offerings to provide the best possible virtual primary care from home with its Home Smart Clinic. By expanding its clinical decision support, Tyto Insights for Wheeze Detection bolsters the Home Smart Clinic’s support of acute care and long-term care for chronic conditions, many of which are respiratory in nature, and helps to alleviate challenges posed by the ongoing healthcare professional shortage. To date, TytoCare has found that respiratory diagnoses constitute over 40% of all diagnoses made using its virtual care solution, reflecting both the common nature of respiratory illnesses and conditions including asthma across patient populations, as well as TytoCare’s unique ability to provide optimal virtual care for the large numbers of patients with respiratory symptoms by offering remote auscultation.

“Our Tyto Insight capabilities, including our wheeze detection algorithm, furthers our goal of enhancing the virtual care experience for all patients, clinicians, providers, and health plans – not just by increasing the quality of care and expanding our chronic care management capabilities, but also by further assisting clinicians and specialists to make informed and accurate diagnoses remotely,” said Dedi Gilad, CEO and Co-Founder of TytoCare. “At TytoCare, we have the world’s largest database of lung and heart sounds, as well as related symtoms and vital signs, and we will continue to leverage it to provide superb quality of care for families worldwide.”

TytoCare’s Home Smart Clinic was introduced to solve the Home Healthcare Delivery Gap™ that patients experience with traditional audio/video-only telehealth solutions. The solution combines TytoCare’s FDA-cleared handheld remote examination device, the AI-backed Tyto Insights™ smart diagnosis support, including the Wheeze Detection, and the Tyto Engagement Labs™ configured for each specific program and cohort to provide high-quality, accessible virtual care in the home and enable health plans and providers to deliver on expected ROI and drive improved health outcomes. The Tyto Insights for Wheeze Detection already bears the CE Mark for usage by clinicians in Europe.

Tagged With: Acute Care, AI, Artificial Intelligence, Asthma, care management, chronic care, Clinical Decision Support, decision support, FDA, FDA Clearance, healthcare delivery, Heart, home healthcare, lung, Primary Care, remote examination, telehealth, TytoCare, video, Virtual Care, Virtual Primary Care, Vital

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Survey: Clinician Burnout Is A Public Health Crisis Demanding Urgent Action

17 Execs Share How Health IT Can Address Clinician Burnout, Staffing, & Capacity

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |